E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Conditions

Cancer

Brief summary

The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.

Alongi F, Nicosia L, Ricardi U, Scorsetti M, Greto D, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Simek IM, Peulen H, Dirix P, Verbeke L, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Fortpied C, Boakye Oppong F, Ost P, Guckenberger M.

2024-07-319 citations

10.1016/j.radonc.2024.110466

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E<sup>2</sup>-RADIatE OligoCare study.

Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M.

2024-03-1915 citations

10.1016/j.radonc.2024.110235

Prospective randomized clinical studies involving reirradiation: update of a systematic review.

Nieder C, Willmann J, Andratschke NH.

2023-07-279 citations

10.1007/s00066-023-02118-1

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Inclusion criteria

* Pathologically confirmed cancer. * Written informed consent for E²-RADIatE according to applicable legal and ethical requirements * Planned use of radiotherapy * Eligibility of the patient confirmed for at least one cohort confirmed * Patients of 12 years and older

Design outcomes

Primary

Measure	Time frame
Number of patients treated with radiotherapy enrolled in the program	5 years

Secondary

Measure	Time frame
Disease free survival	5 years
Loco-regional control	5 years
Distant metastasis free survival	5 years
Overall survival	5 years
Incidence of adverse events related to radiotherapy	5 years

Countries

Austria, Belgium, Czechia, France, Germany, Ireland, Israel, Italy, Netherlands, Poland, Slovenia, Spain, Switzerland, United Kingdom

Contacts

Primary ContactEORTC HQ

1811@eortc.org+32 2 774 1611

Outcome results